Dhaval Shah

Prof. Dhaval Shah

University at Buffalo School of Pharmacy and Pharmaceutical Sciences
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
MKMokshada Kumar
Mokshada Kumar
PKPriyanka Kulkarni
Priyanka Kulkarni
SLShufang Liu
Shufang Liu
NCNagendra Chemuturi
Nagendra Chemuturi
Dhaval ShahDhaval Shah
Dhaval Shah
The objective of this manuscript is to provide quantitative insights into the tissue distribution of nanoparticles. Published pharmacokinetics of nanoparticles in plasma, tumor and 13 different tissues of mice were collected from literature. A total of 2018 datasets were analyzed and biodistribution of graphene oxide, lipid, polymeric, silica, iron oxide and gold nanoparticles in different tissues was quantitatively characterized using Nanoparticle Biodistribution Coefficients (NBC). It was observed that typically after intravenous administration most of the nanoparticles are accumulated in the liver (NBC = 17.56 %ID/g) and spleen (NBC = 12.1 %ID/g), while other tissues received less than 5 %ID/g. NBC values for kidney, lungs, heart, bones, brain, stomach, intestine, pancreas, skin, muscle and tumor were found to be 3.1 %ID/g, 2.8 %ID/g, 1.8 %ID/g, 0.9 %ID/g, 0.3 %ID/g, 1.2 %ID/g, 1.8 %ID/g, 1.2 %ID/g, 1.0 %ID/g, 0.6 %ID/g and 3.4 %ID/g, respectively. Significant variability in nanoparticle distribution was observed in certain organs such as liver, spleen and lungs. A large fraction of this variability could be explained by accounting for the differences in nanoparticle physicochemical properties such as size and material. A critical overview of published nanoparticle physiologically-based pharmacokinetic (PBPK) models is provided, and limitations in our current knowledge about in vitro and in vivo pharmacokinetics of nanoparticles that restrict the development of robust PBPK models is also discussed. It is hypothesized that robust quantitative assessment of whole-body pharmacokinetics of nanoparticles and development of mathematical models that can predict their disposition can improve the probability of successful clinical translation of these modalities.

26 September 2016 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
ASAman P. Singh
Aman P. Singh
SSSharad Sharma
Sharad Sharma
Dhaval ShahDhaval Shah
Dhaval Shah

21 May 2019 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
HCHsueh-Yuan Chang
Hsueh-Yuan Chang
SWShengjia Wu
Shengjia Wu
GMGuy Meno-Tetang
Guy Meno-Tetang
Dhaval ShahDhaval Shah
Dhaval Shah

6 August 2018 in mAbs
Verified
Journal Article
Closed access
HCHsueh-Yuan Chang
Hsueh-Yuan Chang
KMKasey Morrow
Kasey Morrow
EBEmily Bonacquisti
Emily Bonacquisti
WZWanYing Zhang
WanYing Zhang
Dhaval ShahDhaval Shah
Dhaval Shah
Here, we present the first case-study where microdialysis is used to investigate the pharmacokinetics of antibody in different regions of rat brain. Endogenous IgG was used to understand antibody disposition at steady-state and exogenously administered trastuzumab was used to understand the disposition in a dynamic setting. Microdialysis samples from the striatum (ST), lateral ventricle (LV), and cisterna magna (CM) were collected, along with plasma and brain homogenate, to comprehensively understand brain pharmacokinetics of antibodies. Antibody concentrations in cerebrospinal fluid (CSF) were found to vary based on the site-of-collection, where CM concentrations were several-fold higher than LV. In addition, antibody concentrations in CSF (CM/LV) were found to not accurately represent the concentrations of antibody inside brain parenchyma (e.g., ST). Elimination of CSF from CM was found to be slower than LV, and the entry and exit of antibody from ST was also slower. Pharmacokinetics of exogenously administered antibody revealed that the entry of antibody into LV via the blood-CSF barrier may represent an early pathway for antibody entry into the brain. Plasma concentrations of antibody were 247–667, 104–184, 165–435, and 377–909 fold higher than the antibody concentrations in LV, CM, ST, and brain homogenate. It was found that the measurement of antibody pharmacokinetics in different regions of the brain using microdialysis provides an unprecedented insight into brain disposition of antibody. This insight can help in designing better molecules, dosing regimens, and route of administration, which can in turn improve the efficacy of antibodies for central nervous system disorders.

14 January 2020 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
ASAman P. Singh
Aman P. Singh
LGLeiming Guo
Leiming Guo
AVAshwni Verma
Ashwni Verma
GWGloria Gao-Li Wong
Gloria Gao-Li Wong
GTGreg M. Thurber
Greg M. Thurber
Dhaval ShahDhaval Shah
Dhaval Shah

1 March 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
ECEkram Ahmed Chowdhury
Ekram Ahmed Chowdhury
GMGuy Meno-Tetang
Guy Meno-Tetang
HCHsueh Yuan Chang
Hsueh Yuan Chang
SWShengjia Wu
Shengjia Wu
HHHsien Wei Huang
Hsien Wei Huang
Dhaval ShahDhaval Shah
Dhaval Shah